RCM Technologies grows revenue 20 percent: what it means for RCM Technologies stock

Published on 10/06/2026 at 11:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted earnings per share rose 18.80 percent in the second quarter. For RCM Technologies stock, cash reached USD 6.6 million from USD 2.9 million.

RCMT, US7493604000, Illustration mit AI erstellt.

RCM Technologies (ISIN US7493604000) reported revenue of USD 93.8 million in the second quarter of 2026, up 20.00 percent from USD 78.2 million a year earlier. In its release dated August 13, 2026, RCM Technologies also reported stronger adjusted earnings, giving the company a sharper growth profile than its staffing label suggests.

Revenue growth reaches 20.00 percent

Gross profit increased 8.10 percent to USD 24.1 million in the second quarter of 2026 from USD 22.3 million in the comparable quarter. The company reported GAAP net income of USD 4.9 million, or USD 0.68 per diluted share, compared with USD 3.8 million, or USD 0.50 per diluted share, in the prior-year quarter, according to RCM Technologies.

The operating mix was important. Engineering revenue increased 49.00 percent year over year in the second quarter, while Specialty Health Care supplied a steadier business base, according to Zacks on September 29, 2026.

Cash and targets move higher

Adjusted EBITDA rose 14.80 percent to USD 9.3 million in the second quarter of 2026 from USD 8.1 million, while adjusted earnings per share increased 18.80 percent to USD 0.82 from USD 0.69. For the first half of 2026, adjusted EBITDA reached USD 17.5 million, up 9.90 percent year over year, according to RCM Technologies.

Cash stood at USD 6.6 million on July 4, 2026, compared with USD 2.9 million at the beginning of the year. Analyst coverage also moved upward: MarketBeat reported that Benchmark raised its target from USD 36.00 to USD 45.00 and B. Riley Financial lifted its target from USD 40.00 to USD 45.00 in reports dated August 17, 2026.

Range and next report date

RCMT had a market capitalization of USD 294.8 million as of October 5, 2026. Its 52-week range was USD 17.26 to USD 43.09 on the same date, placing the upper end of the range 149.65 percent above the lower end and underscoring the stock's expanded valuation profile.

TradingView lists November 11, 2026 as the next earnings date. The next report will show whether Engineering growth can continue to offset the more measured pace of the health care business.